The second domestic third-generation EGFR-TKI was approved for listing

According to the latest news from the official website of the State Food and Drug Administration, the core product of Iris, the irreversible and highly selective third-generation EGFR inhibitor vometinib mesylate tablets, has been approved for marketing.

It is understood that Iris vometinib mesylate has been approved for the treatment of locally advanced or metastatic non-small cell lung cancer ( NSCLC ) with positive EGFR T790M mutations .

It is understood that the targeted drugs for the first-line treatment indications for the above-mentioned advanced non-small cell lung cancer currently on the market in China include the first-generation, second-generation and third-generation EGFR-TKIs.

According to Frost & Sullivan’s market data, in 2018 China’s EGFR-TKI drug market, the third-generation market share has reached 38%, the first-generation drug market share is 57%, and the second-generation drug only 5% It is expected that the market share of the third-generation EGFR-TKI will further increase in the future.

In March 2017, the first third-generation EGFR-TKI ossitinib was officially approved for marketing in my country.

In March 2020, Hausen Pharmaceutical's Ametinib was approved by the National Food and Drug Administration.

It is also worth noting that Avitinib, which was once high hopes, is currently in clinical research and development.